Crispr Therapeutics AG (CRSP) Receives a Buy from Bank of America Securities

In a report released today, Geoff Meacham from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report). The company’s shares opened today at $53.38.

According to TipRanks, Meacham is a 4-star analyst with an average return of 3.0% and a 49.46% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Eli Lilly & Co, and Moderna.

In addition to Bank of America Securities, Crispr Therapeutics AG also received a Buy from Oppenheimer’s Jay Olson in a report issued on May 10. However, on the same day, Stifel Nicolaus maintained a Hold rating on Crispr Therapeutics AG (NASDAQ: CRSP).

Based on Crispr Therapeutics AG’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $201.21 million and a net profit of $89.35 million. In comparison, last year the company earned a revenue of $768 thousand and had a GAAP net loss of $110.58 million

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CRSP in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Crispr Therapeutics AG (CRSP) Company Description:

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.